Ibio (IBIO) Competitors $0.85 +0.05 (+6.16%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock IBIO vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Ibio stock or one of its competitors? The main competitors of Ibio include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Ibio vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity Ibio (NASDAQ:IBIO) and 180 Life Sciences (NASDAQ:ATNFW) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Which has higher earnings & valuation, IBIO or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than Ibio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIbio$400K43.02-$35.24M-$1.74-0.49180 Life SciencesN/AN/AN/AN/AN/A Do analysts recommend IBIO or ATNFW? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ibio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IBIO or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets IbioN/A N/A N/A 180 Life Sciences N/A N/A N/A Do institutionals & insiders hold more shares of IBIO or ATNFW? 7.9% of Ibio shares are held by institutional investors. 2.8% of Ibio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to IBIO or ATNFW? In the previous week, Ibio had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Ibio and 0 mentions for 180 Life Sciences. Ibio's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Ibio Neutral 180 Life Sciences Neutral SummaryIbio beats 180 Life Sciences on 5 of the 5 factors compared between the two stocks. Get Ibio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetricIbioPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$17.21M$1.02B$2.51B$10.51BDividend YieldN/A4.84%2.52%4.80%P/E Ratio-0.491.2726.0927.35Price / Sales43.02182.45290.83196.40Price / CashN/A17.6447.0861.53Price / BookN/A7.7840.066.82Net Income-$35.24M-$7.59M$6.97M$276.80M7 Day PerformanceN/A-1.17%-0.56%0.26%1 Month PerformanceN/A26.03%1.23%8.29%1 Year PerformanceN/A-10.14%70.71%35.59% Ibio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOIbioN/A$0.85+6.2%N/AN/A$17.21M$400K-0.49100News CoverageAnalyst UpgradeATNFW180 Life SciencesN/A$0.06+0.7%N/A+653.3%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.16-25.2%N/A+227.1%$0.00$110.87K0.0040Gap UpALVOWAlvotechN/A$1.60+6.7%N/A-45.0%$0.00$560.10M0.004ARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+12.9%N/A-40.6%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10+2.9%N/A+400.0%$0.00$39.19M0.0070Gap UpBTMDWbioteN/A$0.01-15.8%N/A-99.4%$0.00$199.07M0.00N/AHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.06-0.2%N/A-82.3%$0.00N/A0.008Negative NewsGap DownCELUWCelularityN/A$0.03-10.0%N/A+112.8%$0.00$44.59M0.00220Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Ainos Alternatives Alvotech Alternatives ARAVIVE Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBIO) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ibio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ibio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
